Research Article
BibTex RIS Cite

Evaluation of Adaptation to Guidelines on the Management of Chronic Obstructive Pulmonary Diseases in Family Medicine

Year 2021, , 497 - 503, 18.10.2021
https://doi.org/10.18521/ktd.905234

Abstract

Objective: Chronic Obstructive Pulmonary Disease (COPD) has become increasingly important in recent years. The CAT (COPD Assessment Test) and mMRC (Modified British Medical Research Council) scales can be used in the clinical evaluation of the patients according to GOLD the COPD Protection Diagnosis and Treatment Guideline guideline. Patients were divided into groups A, B, C and D using the scales with the combined assessment scheme proposed by GOLD, and recommended treatment scheme for each step is determined. In this study, it is planned to investigate whether COPD patients getting the optimal treatment according to GOLD guideline. It is also aimed to expand the use of these scales in Family Medicine practice, which helps understanding the clinical status of patients.
Method: This is a descriptive, cross-sectional study. 218 patients were included in the study. The questionnaire form of the study was applied to the patients and the patients were evaluated and scored with the help of these scales. Statistical analysis of the data obtained in this way was done by the SPSS program.
Result: According to the CAT result, compliance with the guideline was 8.4% in group A, 22.3% in group B, 5.8% in group C and 77% in group D. In the evaluation made according to the mMRC result, compliance with the guideline was 12.5% in group A, 24.7% in group B, 0% in group C, and 77.7% in group D. It was determined that only 40.8% of patients according to mMRC and only 33% according to CAT were receiving the optimal treatment that was completely suitable for their groups.
Conclusion: Patients with stable COPD had significantly higher use of bronchodilator drugs than recommended. The use of this scale by Family Doctors, will be important in determining the needs for treatment and COPD patients follow-up.

References

  • [1] GOLD, Global Initiative for Chronic Obstructive, G Glob. Obst. Lung Dis., P. http://www.goldcopd.org, 2018.
  • [2] A. Kocabas et al., RAPOR Turkish Thoracic Society COPD Study Group Chronic Obstructive Pulmonary Disease (COPD) Protection, Diagnosis and Treatment Report 2014, aş Turkısh Thorac. J., vol. 15, 2014.
  • [3] B. E. T. ACICAN and GULBAY, Turkey clinics. Endocrinology, vol. 1, no. 49. Ortadoğu Advertising Promotion and Publishing, 2005.
  • [4] H. Gunen et al., Document Categorization of COPD patients in Turkey via GOLD 2013 strategy document: ALPHABET study., H. Int. J. Chron. Obstruct. The Pulmo. Dis., Vol. 10, pp. 2485594, 2015.
  • [5] J. M. Marin et al., “The COCOMICS study.,] Eur. Respir. J., vol. 42, no. 2, pp. 323.32, Aug. 2013.
  • [6] S. Holt, D. Sheahan, C. Helm, C. Tofield, A. Corin, and JWH Kocks, W Little agreement in GOLD category. Premium. care Respir. Med., Vol. 24, p. 14025, Jul. 2014.
  • [7] J. B. Soriano et al., & Quot; Distribution and Prognostic & lt; RTI ID = 0.0 & gt; Validity of the New & lt; / RTI & gt; 143, no. 3, pp. 694 Mar702, Mar. 2013.
  • [8] B. Lamprecht et al.,, COPD in Never Smokers, Lamp Chest, vol. 139, no. 4, pp. 752 Apr763, Apr. 2011.
  • [9] M. K. Han et al., Ective GOLD 2011 disease severity classification in COPD Gene: a prospective cohort study. Respir. Med., Vol. 1, no. 1, pp. 43.50, Mar. 2013.
  • [10] P. W. Jones, G. Nadeau, M. Small, and L. Adamek, of Characteristics of a COPD categorized using the GOLD framework, M. Respir. Med., Vol. 108, no. 1, pp. 129.135, Jan. 2014.
  • [11] KA Safka, FCJ Wald, FCH Wang, L. Mcivor, A. Mcivor, and C. Frcp, FC Journal of the COPD Foundation ”Vol. 4, no. 1, pp. 45 .55, 2017.

Kronik Obstuktif Akciğer Hastalığı Tedavisinde Rehberlere Uyumun Aile Hekimliğinde Değerlendirilmesi

Year 2021, , 497 - 503, 18.10.2021
https://doi.org/10.18521/ktd.905234

Abstract

Amaç: Kronik Obstrüktif Akciğer Hastalığı (KOAH) solunum yollarının kısıtlamasıyla karakterize bir hastalık olup son yıllarda hasta sayısının ve hastalığın morbidite-mortalitesinin artması sebebiyle önemi giderek artmaktadır. KOAH rehberlerine göre ilgili hastaların klinik değerlendirmesinde CAT (COPD Assessment Test) ve mMRC (Modified British Medical Research Council) ölçekleri kullanılabilmektedir. GOLD (Global Initiative for Chronic Obstructive Lung Disease) KOAH Koruma Tanı ve Tedavi Kılavuzunun önerdiği birleşik değerlendirme şemasıyla hastalar bahsedilen ölçekler kullanılarak A, B, C ve D gruplarına ayrılmıştır ve her basamak için önerilen tedavi belirlenmiştir. Bu çalışmada inhaler tedavi kullanan KOAH hastalarının GOLD önerilerine göre optimum tedaviyi alıp almadığının araştırılması amaçlanmıştır.
Yöntem: Araştırma tanımlayıcı, kesitsel tipte bir araştırmadır. Hastalığının son üç ayında tedavi değişikliği yapılmamış ve aktif yakınması olmayan KOAH hastalarından araştırmamıza katılmayı kabul edenler çalışmaya dahil edilmiştir. Çalışmanın anket formu hastalara uygulanmış ve bu ölçekler yardımı ile hastalar değerlendirilmiştir. Hastanın aldığı tedavinin rehberlerle uyumlu olup olmadığı araştırılmıştır. Bu şekilde elde edilen verilerin istatiksel analizi SPSS programı ile yapılmıştır.
Bulgular: CAT sonucuna göre yapılan değerlendirmede tedavide kılavuza uyum A grubunda %9,8, B grubunda %22,3, C grubunda %5,8, D grubunda %77,7 bulundu. mMRC sonucuna göre yapılan değerlendirmede tedavide kılavuza uyum A, B, C, D gruplarında sırasıyla %12,5, %24,4, %14,2, %80,8 bulundu. Sonuçlar değerlendirildiğinde mMRC’ye göre hastaların %40,8’i, CAT’e göre ise %33’ü gruplarına tam olarak uygun olan tedaviyi almaktadır.
Sonuç: Stabil dönem KOAH hastalarında azımsanmayacak bir oranda önerilenden daha yüksek grup bronkodilatör ilaç kullanımı olduğu saptanmıştır. Bu ölçeklerin aile hekimleri tarafından kullanılmasının, stabil dönem KOAH hastalarının takibi ve tedavi ihtiyaçlarının belirlenmesinde önemli olacağı düşünülmüştür.

References

  • [1] GOLD, Global Initiative for Chronic Obstructive, G Glob. Obst. Lung Dis., P. http://www.goldcopd.org, 2018.
  • [2] A. Kocabas et al., RAPOR Turkish Thoracic Society COPD Study Group Chronic Obstructive Pulmonary Disease (COPD) Protection, Diagnosis and Treatment Report 2014, aş Turkısh Thorac. J., vol. 15, 2014.
  • [3] B. E. T. ACICAN and GULBAY, Turkey clinics. Endocrinology, vol. 1, no. 49. Ortadoğu Advertising Promotion and Publishing, 2005.
  • [4] H. Gunen et al., Document Categorization of COPD patients in Turkey via GOLD 2013 strategy document: ALPHABET study., H. Int. J. Chron. Obstruct. The Pulmo. Dis., Vol. 10, pp. 2485594, 2015.
  • [5] J. M. Marin et al., “The COCOMICS study.,] Eur. Respir. J., vol. 42, no. 2, pp. 323.32, Aug. 2013.
  • [6] S. Holt, D. Sheahan, C. Helm, C. Tofield, A. Corin, and JWH Kocks, W Little agreement in GOLD category. Premium. care Respir. Med., Vol. 24, p. 14025, Jul. 2014.
  • [7] J. B. Soriano et al., & Quot; Distribution and Prognostic & lt; RTI ID = 0.0 & gt; Validity of the New & lt; / RTI & gt; 143, no. 3, pp. 694 Mar702, Mar. 2013.
  • [8] B. Lamprecht et al.,, COPD in Never Smokers, Lamp Chest, vol. 139, no. 4, pp. 752 Apr763, Apr. 2011.
  • [9] M. K. Han et al., Ective GOLD 2011 disease severity classification in COPD Gene: a prospective cohort study. Respir. Med., Vol. 1, no. 1, pp. 43.50, Mar. 2013.
  • [10] P. W. Jones, G. Nadeau, M. Small, and L. Adamek, of Characteristics of a COPD categorized using the GOLD framework, M. Respir. Med., Vol. 108, no. 1, pp. 129.135, Jan. 2014.
  • [11] KA Safka, FCJ Wald, FCH Wang, L. Mcivor, A. Mcivor, and C. Frcp, FC Journal of the COPD Foundation ”Vol. 4, no. 1, pp. 45 .55, 2017.
There are 11 citations in total.

Details

Primary Language English
Subjects Health Care Administration
Journal Section Articles
Authors

Öznur Kübra Odabaş 0000-0001-6546-5261

Deniz Doğan 0000-0003-2596-3113

Tarık Eren Yılmaz 0000-0003-2745-9527

Adem Özkara 0000-0003-1658-3071

Publication Date October 18, 2021
Acceptance Date September 3, 2021
Published in Issue Year 2021

Cite

APA Odabaş, Ö. K., Doğan, D., Yılmaz, T. E., Özkara, A. (2021). Evaluation of Adaptation to Guidelines on the Management of Chronic Obstructive Pulmonary Diseases in Family Medicine. Konuralp Medical Journal, 13(3), 497-503. https://doi.org/10.18521/ktd.905234
AMA Odabaş ÖK, Doğan D, Yılmaz TE, Özkara A. Evaluation of Adaptation to Guidelines on the Management of Chronic Obstructive Pulmonary Diseases in Family Medicine. Konuralp Medical Journal. October 2021;13(3):497-503. doi:10.18521/ktd.905234
Chicago Odabaş, Öznur Kübra, Deniz Doğan, Tarık Eren Yılmaz, and Adem Özkara. “Evaluation of Adaptation to Guidelines on the Management of Chronic Obstructive Pulmonary Diseases in Family Medicine”. Konuralp Medical Journal 13, no. 3 (October 2021): 497-503. https://doi.org/10.18521/ktd.905234.
EndNote Odabaş ÖK, Doğan D, Yılmaz TE, Özkara A (October 1, 2021) Evaluation of Adaptation to Guidelines on the Management of Chronic Obstructive Pulmonary Diseases in Family Medicine. Konuralp Medical Journal 13 3 497–503.
IEEE Ö. K. Odabaş, D. Doğan, T. E. Yılmaz, and A. Özkara, “Evaluation of Adaptation to Guidelines on the Management of Chronic Obstructive Pulmonary Diseases in Family Medicine”, Konuralp Medical Journal, vol. 13, no. 3, pp. 497–503, 2021, doi: 10.18521/ktd.905234.
ISNAD Odabaş, Öznur Kübra et al. “Evaluation of Adaptation to Guidelines on the Management of Chronic Obstructive Pulmonary Diseases in Family Medicine”. Konuralp Medical Journal 13/3 (October 2021), 497-503. https://doi.org/10.18521/ktd.905234.
JAMA Odabaş ÖK, Doğan D, Yılmaz TE, Özkara A. Evaluation of Adaptation to Guidelines on the Management of Chronic Obstructive Pulmonary Diseases in Family Medicine. Konuralp Medical Journal. 2021;13:497–503.
MLA Odabaş, Öznur Kübra et al. “Evaluation of Adaptation to Guidelines on the Management of Chronic Obstructive Pulmonary Diseases in Family Medicine”. Konuralp Medical Journal, vol. 13, no. 3, 2021, pp. 497-03, doi:10.18521/ktd.905234.
Vancouver Odabaş ÖK, Doğan D, Yılmaz TE, Özkara A. Evaluation of Adaptation to Guidelines on the Management of Chronic Obstructive Pulmonary Diseases in Family Medicine. Konuralp Medical Journal. 2021;13(3):497-503.